CN112341525B - 一种重组非洲猪瘟病毒pE120R亚单位可溶性蛋白及其制备方法和应用 - Google Patents
一种重组非洲猪瘟病毒pE120R亚单位可溶性蛋白及其制备方法和应用 Download PDFInfo
- Publication number
- CN112341525B CN112341525B CN201910732340.6A CN201910732340A CN112341525B CN 112341525 B CN112341525 B CN 112341525B CN 201910732340 A CN201910732340 A CN 201910732340A CN 112341525 B CN112341525 B CN 112341525B
- Authority
- CN
- China
- Prior art keywords
- pe120r
- swine fever
- african swine
- protein
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101710191636 Protein p14.5 Proteins 0.000 title claims abstract description 80
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 60
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 46
- 241000701386 African swine fever virus Species 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 238000001814 protein method Methods 0.000 title description 2
- 208000007407 African swine fever Diseases 0.000 claims abstract description 32
- 239000013612 plasmid Substances 0.000 claims abstract description 18
- 241000588724 Escherichia coli Species 0.000 claims abstract description 15
- 238000012258 culturing Methods 0.000 claims abstract description 14
- 108020004705 Codon Proteins 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 10
- 230000009465 prokaryotic expression Effects 0.000 claims abstract description 9
- 239000013604 expression vector Substances 0.000 claims abstract description 7
- 238000010367 cloning Methods 0.000 claims abstract description 3
- 238000003259 recombinant expression Methods 0.000 claims abstract description 3
- 238000012216 screening Methods 0.000 claims abstract description 3
- 238000000855 fermentation Methods 0.000 claims description 40
- 230000004151 fermentation Effects 0.000 claims description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 12
- 239000000306 component Substances 0.000 claims description 11
- 230000006698 induction Effects 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 10
- 239000002609 medium Substances 0.000 claims description 10
- 239000012533 medium component Substances 0.000 claims description 10
- 239000012526 feed medium Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000011081 inoculation Methods 0.000 claims description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 6
- 240000000220 Panda oleosa Species 0.000 claims description 4
- 235000016496 Panda oleosa Nutrition 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000012137 tryptone Substances 0.000 claims description 4
- 239000006052 feed supplement Substances 0.000 claims description 3
- 230000001502 supplementing effect Effects 0.000 claims description 3
- 239000007836 KH2PO4 Substances 0.000 claims description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000013530 defoamer Substances 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 11
- 101710172711 Structural protein Proteins 0.000 abstract description 6
- 108010087302 Viral Structural Proteins Proteins 0.000 abstract description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 21
- 238000001179 sorption measurement Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 229910001868 water Inorganic materials 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000005457 optimization Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 241001052560 Thallis Species 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000282887 Suidae Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000001976 enzyme digestion Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101710121996 Hexon protein p72 Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical group CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000110 cooling liquid Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910732340.6A CN112341525B (zh) | 2019-08-09 | 2019-08-09 | 一种重组非洲猪瘟病毒pE120R亚单位可溶性蛋白及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910732340.6A CN112341525B (zh) | 2019-08-09 | 2019-08-09 | 一种重组非洲猪瘟病毒pE120R亚单位可溶性蛋白及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112341525A CN112341525A (zh) | 2021-02-09 |
CN112341525B true CN112341525B (zh) | 2024-02-09 |
Family
ID=74367489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910732340.6A Active CN112341525B (zh) | 2019-08-09 | 2019-08-09 | 一种重组非洲猪瘟病毒pE120R亚单位可溶性蛋白及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112341525B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116396974B (zh) * | 2022-02-21 | 2024-02-13 | 吉林农业大学 | 非洲猪瘟病毒抗原蛋白重组表达载体、重组植物乳酸菌及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103805615A (zh) * | 2014-02-19 | 2014-05-21 | 孙洁 | 密码子优化的非洲猪瘟病毒p54基因、其核酸疫苗及应用 |
CN108148138A (zh) * | 2017-12-14 | 2018-06-12 | 石河子大学 | 非洲猪瘟病毒多表位融合诊断抗原及其制备方法和用途 |
CN110041411A (zh) * | 2018-01-15 | 2019-07-23 | 浙江海隆生物科技有限公司 | 稳定的非典型猪瘟病毒亚单位蛋白及其疫苗和制备方法和应用 |
-
2019
- 2019-08-09 CN CN201910732340.6A patent/CN112341525B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103805615A (zh) * | 2014-02-19 | 2014-05-21 | 孙洁 | 密码子优化的非洲猪瘟病毒p54基因、其核酸疫苗及应用 |
CN108148138A (zh) * | 2017-12-14 | 2018-06-12 | 石河子大学 | 非洲猪瘟病毒多表位融合诊断抗原及其制备方法和用途 |
CN110041411A (zh) * | 2018-01-15 | 2019-07-23 | 浙江海隆生物科技有限公司 | 稳定的非典型猪瘟病毒亚单位蛋白及其疫苗和制备方法和应用 |
Non-Patent Citations (4)
Title |
---|
Martinez-Pomares L等.Characterization of the African swine fever virus structural protein p14. 5: a DNA binding protein.《Virology》.1997,第229卷(第01期),第201-211页. * |
Martinez-Pomares L等.Characterization of the African swine fever virus structural protein p14. 5: a DNA binding protein.Virology.1997,第229卷(第01期),第201-211页. * |
佚名.P14_ASFWA.《Uniprot》.2019,第1-2页. * |
欧云文等.非洲猪瘟病毒结构蛋白在病毒感染过程中的作用.《生物技术通报》.2019,第35卷(第06期),第156-163页. * |
Also Published As
Publication number | Publication date |
---|---|
CN112341525A (zh) | 2021-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110078801B (zh) | 一种高效表达非洲猪瘟cd2v蛋白的cho细胞株 | |
CN111607001B (zh) | 一种重组的非洲猪瘟病毒p72亚单位可溶性融合蛋白及其制备方法和应用 | |
CN111471089B (zh) | 一种重组的非洲猪瘟病毒cd2v亚单位蛋白及其制备方法和应用 | |
CN110105436B (zh) | 猪圆环病毒3型抗体的elisa检测试剂盒及其制备方法与应用 | |
CN111393531B (zh) | 一种亚单位融合蛋白CD2V-Fc及其制备方法和应用 | |
CN110041411B (zh) | 稳定的非典型猪瘟病毒亚单位蛋白及其疫苗和制备方法和应用 | |
CN111777672A (zh) | 一种重组的非洲猪瘟病毒pKP177R亚单位可溶性蛋白及其制备方法和应用 | |
WO2020238458A1 (zh) | 用于表达e2蛋白的细胞株及其应用,e2蛋白及其应用 | |
CN107664697B (zh) | 表达载体及其制备方法、pedv-s1蛋白及包含该蛋白的间接elisa检测试剂盒 | |
CN116396959A (zh) | 抗猪星状病毒五型PAstV5单克隆抗体、引物、杂交瘤细胞株、制备、应用 | |
CN116217737A (zh) | 非洲猪瘟病毒免疫原的p49突变融合蛋白、重组载体、工程菌及制备方法和应用 | |
CN112341525B (zh) | 一种重组非洲猪瘟病毒pE120R亚单位可溶性蛋白及其制备方法和应用 | |
CN110845624A (zh) | 一种sumo-cp融合蛋白及其制备方法以及其多克隆抗体的制备方法 | |
CN113637069A (zh) | 猪圆环病毒4型Cap蛋白单克隆抗体及其制备方法和应用 | |
CN113150126A (zh) | 一种兔源抗猪细小病毒6型vp2蛋白抗体及其制备方法 | |
CN111607000B (zh) | 一种重组的非洲猪瘟病毒p30亚单位可溶性融合蛋白及其制备方法和应用 | |
CN112142827B (zh) | 一种猪伪狂犬病毒的gB亚单位重组蛋白及其制备方法和应用 | |
CN115073559A (zh) | 重组的非洲猪瘟病毒ep153r亚单位跨膜蛋白的原核可溶性表达方法和应用 | |
CN115074372B (zh) | 一种重组的非洲猪瘟病毒j18l亚单位蛋白及其制备方法和应用 | |
CN113512098B (zh) | 鉴别猪瘟病毒和牛病毒性腹泻病毒血清抗体间接elisa方法及其应用 | |
CN113735943A (zh) | 一种重组的非洲猪瘟病毒p72亚单位蛋白和制备方法及其应用 | |
CN116203245A (zh) | 一种盖塔病毒抗体胶体金免疫层析试纸条及其制备方法 | |
CN115073558A (zh) | 一种重组的非洲猪瘟病毒dp96r亚单位蛋白及其制备方法和应用 | |
CN113817027A (zh) | 一种牛疱疹病毒Ⅰ型gE蛋白胞外区的原核可溶性表达方法 | |
CN115074372A (zh) | 一种重组的非洲猪瘟病毒j18l亚单位蛋白及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 312366 No. 1, Baichuan Road, Binhai New Area, Shaoxing City, Zhejiang Province Applicant after: NOVO BIOTECH Corp. Address before: 312000 5th floor, building 2, science and innovation center, 398 mahuan Road, Binhai New Town, Shaoxing City, Zhejiang Province Applicant before: NOVO BIOTECH Corp. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 312366 No. 1, Baichuan Road, Binhai New Area, Shaoxing City, Zhejiang Province Patentee after: Zhejiang Hailong Biotechnology Co.,Ltd. Country or region after: China Address before: 312366 No. 1, Baichuan Road, Binhai New Area, Shaoxing City, Zhejiang Province Patentee before: NOVO BIOTECH Corp. Country or region before: China |
|
CP03 | Change of name, title or address |